Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3220567
Max Phase: Preclinical
Molecular Formula: C32H65N5O8S
Molecular Weight: 679.97
Molecule Type: Small molecule
Associated Items:
ID: ALA3220567
Max Phase: Preclinical
Molecular Formula: C32H65N5O8S
Molecular Weight: 679.97
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCSC[C@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)[C@@H](O)C[C@H]3N)[C@@H](N)C[C@H]2N)[C@H](O)[C@@H](N)[C@@H]1O
Standard InChI: InChI=1S/C32H65N5O8S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-46-18-24-26(39)25(37)27(40)32(43-24)45-30-20(35)15-19(34)29(28(30)41)44-31-21(36)16-22(38)23(17-33)42-31/h19-32,38-41H,2-18,33-37H2,1H3/t19-,20+,21+,22-,23+,24+,25-,26+,27+,28-,29+,30-,31+,32+/m0/s1
Standard InChI Key: GQRDJNCMJBERTJ-GWEZSMEQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 679.97 | Molecular Weight (Monoisotopic): 679.4554 | AlogP: 0.15 | #Rotatable Bonds: 20 |
Polar Surface Area: 247.94 | Molecular Species: BASE | HBA: 14 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 13 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.54 | CX Basic pKa: 9.68 | CX LogP: 0.67 | CX LogD: -6.30 |
Aromatic Rings: 0 | Heavy Atoms: 46 | QED Weighted: 0.08 | Np Likeness Score: 0.79 |
1. Herzog IM, Feldman M, Eldar-Boock A, Satchi-Fainaro R, Fridman M. (2013) Design of membrane targeting tobramycin-based cationic amphiphiles with reduced hemolytic activity, 4 (1): [10.1039/C2MD20162C] |
2. Fosso MY, Shrestha SK, Green KD, Garneau-Tsodikova S.. (2015) Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles., 58 (23): [PMID:26592740] [10.1021/acs.jmedchem.5b01375] |
Source(1):